Arrowhead Pharma (ARWR) PT Raised to $40 at Morgan Stanley
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $86.64 +1.23%
Rating Summary:
17 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Morgan Stanley analyst Michael E Ulz raised the price target on Arrowhead Pharma (NASDAQ: ARWR) to $40.00 (from $37.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- CAE Inc. (CAE:CN) (CAE) PT Raised to Cdn$49 at Desjardins
- Indigo Paints (INDIGOPN:IN) PT Raised to INR1,300 at ICICI Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
